Add time:08/15/2019         Source:sciencedirect.com

Further investigation of the potential anticonvulsant activity of the enaminones was attempted to discern the possible role of metabolites as the active/co-active entities of the esters of the enaminones. A series of 5-methyl-2-cyclohexene enaminones, the hypothesised metabolites corresponding to a sequence of active and inactive esters were synthesised and evaluated for anticonvulsant activity. With two exceptions, ethyl 4-[(4-cyanophenyl)amino]-6-methyl-2-oxocyclohex-3-ene-1-carboxylate (1k), and 3-[N-(4-cyanophenyl)amino]-5-methyl-2-cyclohexenone (3g), and ethyl 4-(phenylamino)-6-methyl-2-cyclohexenone (1n), and 3-N-(phenylamino)-5-methyl-2-cyclohexenone (3j), anticonvulsant screening data were parallel, with the ester and their putative decarboxylated analogue displaying similar activity. The most active analogue evaluated in this series, ethyl 4-[(4-chlorophenyl)amino]-6-methyl-2-oxocyclohex-3-ene-1-carboxylate (1e), which displayed an ED50 of 16.7 mg kg−1 and a TD50 of 110.7 mg kg−1 (protective index, PI=TD50/ED50=6.6) in the maximal electroshock seizure (MES) test in mice and an ED50 of 3.0 mg kg−1 and a TD50 >250 mg kg−1 (PI >83.3) in rats in the same evaluation, making this compound the most potent enaminone emanating from our laboratories. Pharmacokinetic evaluation of compound 1e in rats using LC/MS analysis unequivocally provides evidence that this compound is converted into the decarboxylated analogue 3a in the brain and the urine.

We also recommend Trading Suppliers and Manufacturers of 5-Amino-5-methyl-2-(p-chlorophenyl)-1,3-dioxane (cas 17144-46-6). Pls Click Website Link as below: cas 17144-46-6 suppliers